Search Results - "RAPPOLD, Erica"

Parsaclisib in Japanese patients with relapsed or refractory B‐cell lymphoma (CITADEL‐111): A phase Ib study by Fukuhara, Noriko, Suehiro, Youko, Kato, Harumi, Kusumoto, Shigeru, Coronado, Cinthya, Rappold, Erica, Zhao, Wanying, Li, Jia, Gilmartin, Aidan, Izutsu, Koji

“…Parsaclisib, a potent, selective, next‐generation PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory B‐cell lymphoma. We…”
Get full text

Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials by Perez, Edith A., MD, Koehler, Maria, MD, PhD, Byrne, Julie, PhD, Preston, Alaknanda J., PhD, Rappold, Erica, BSN, Ewer, Michael S., MD, JD

“…OBJECTIVE To analyze the cardiac safety of lapatinib, an oral, reversible, tyrosine kinase EGFR ( ERBB1 ) and HER2 inhibitor, using prospective data collected…”
Get full text

Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials by Perez, Edith A., Koehler, Maria, Byrne, Julie, Preston, Alaknanda J., Rappold, Erica, Ewer, Michael S.

“…To analyze the cardiac safety of lapatinib, an oral, reversible, tyrosine kinase EGFR ( ERBB1) and HER2 inhibitor, using prospective data collected in 44…”
Get full text

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial by Goss, Paul E, Prof, Smith, Ian E, Prof, O'Shaughnessy, Joyce, MD, Ejlertsen, Bent, Prof, Kaufmann, Manfred, Prof, Boyle, Frances, MBBS, Buzdar, Aman U, Prof, Fumoleau, Pierre, Prof, Gradishar, William, Prof, Martin, Miguel, Prof, Moy, Beverly, MD, Piccart-Gebhart, Martine, MD, Pritchard, Kathleen I, Prof, Lindquist, Deborah, MD, Chavarri-Guerra, Yanin, MD, Aktan, Gursel, MD, Rappold, Erica, BSN, Williams, Lisa S, MSc, Finkelstein, Dianne M, Prof

“…Summary Background Worldwide, many patients with HER2-positive early stage breast cancer do not receive trastuzumab—the standard adjuvant treatment. We…”
Get full text

Safety and Efficacy of Parsaclisib in Combination with Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma: Analysis of a Phase 1 Dose-Finding Study (CITADEL-112) by Sancho, Juan-Manuel, Abrisqueta, Pau, Kumar, Abhijeet, Cordoba, Raul, Tani, Monica, Liu, Teng, Rappold, Erica, Langmuir, Peter, Lopez-Guillermo, Armando

Get full text

Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112) by Sancho, Juan-Manuel, Abrisqueta, Pau, Kumar, Abhijeet, Cordoba, Raul, Tani, Monica, Langmuir, Peter, Rappold, Erica, Liu, Teng, Lopez-Guillermo, Armando

“…Parsaclisib, a potent and highly selective phosphoinositide 3-kinase δ inhibitor, has shown clinical activity in relapsed/refractory (R/R) B-cell lymphoma. The…”
Get full text

Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open‐label study by Barcellini, Wilma, Pane, Fabrizio, Patriarca, Andrea, Murakhovskaya, Irina, Terriou, Louis, DeSancho, Maria T., Hanna, Wahid T., Leopold, Lance, Rappold, Erica, Szeto, Ke, Wei, Shaoceng, Jäger, Ulrich

“…Autoimmune hemolytic anemia (AIHA) is a group of acquired autoimmune disorders characterized by red blood cell hemolysis. In a phase 2, open‐label, multicenter…”
Get full text

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204) by Phillips, Tycel, Avigdor, Abraham, Gurion, Ronit, Patti, Caterina, Corradini, Paolo, Tani, Monica, Mehta, Amitkumar, Lossos, Izidore S., Zinzani, Pier Luigi Luigi, Thieblemont, Catherine, Jurczak, Wojciech, Zheng, Fred, Rappold, Erica, Zhao, Wanying, Johnson, Peter

“…Background: Marginal zone lymphoma (MZL) is the third most common lymphoma in Western countries, accounting for 8-12% of non-Hodgkin lymphoma (Delinger NM…”
Get full text

Prospective Validation of HLA-DRB107:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury by SCHAID, Daniel J, SPRAGGS, Colin F, GOSS, Paul E, MCDONNELL, Shannon K, PARHAM, Laura R, COX, Charles J, EJLERTSEN, Bent, FINKELSTEIN, Dianne M, RAPPOLD, Erica, CURRAN, Joan, CARDON, Lon R

“…Liver injury is a serious adverse event leading to permanent discontinuation of lapatinib in affected patients. This study aimed to validate previously…”
Get full text

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) by Phillips, Tycel J., Corradini, Paolo, Gurion, Ronit, Patti, Caterina, Tani, Monica, Avigdor, Abraham, Jurczak, Wojciech, Mehta, Amitkumar, Zinzani, Pier Luigi, Lossos, Izidore S., Thieblemont, Catherine, Zheng, Fred, Rappold, Erica, Zhao, Wanying, Johnson, Peter

“…Background: Marginal zone lymphoma (MZL) is a clinically heterogeneous, indolent, non-Hodgkin lymphoma (NHL) with 3 subtypes classified as extranodal, nodal,…”
Get full text

Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112) by Sancho, Juan-Manuel, Abrisqueta, Pau, Kumar, Abhijeet, Cordoba, Raul, Tani, Monica, Langmuir, Peter, Rappold, Erica, Liu, Teng, Lopez-Guillermo, Armando

“…Parsaclisib, a potent and highly selective phosphoinositide 3-kinase δ inhibitor, has shown clinical activity in relapsed/refractory (R/R) B-cell lymphoma. The…”
Get full text

A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204) by Phillips, Tycel J., Avigdor, Abraham, Gurion, Ronit, Patti, Caterina, Corradini, Paolo, Tani, Monica, Mehta, Amitkumar, Lossos, Izidore S., Zinzani, Pier Luigi, Thieblemont, Catherine, Jurczak, Wojciech, Zheng, Fred, Rappold, Erica, Zhao, Wanying, Jiang, Ping, Johnson, Peter

“…•Parsaclisib, a highly selective, potent PI3Kδ inhibitor, demonstrated durable responses and an overall manageable safety profile in R/R MZL.•Investigation is…”
Get full text

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy by Strasser-Weippl, Kathrin, Horick, Nora, Smith, Ian E, O'Shaughnessy, Joyce, Ejlertsen, Bent, Boyle, Frances, Buzdar, Aman U, Fumoleau, Pierre, Gradishar, William, Martin, Miguel, Moy, Beverly, Piccart-Gebhart, Martine, Pritchard, Kathleen I, Lindquist, Deborah, Rappold, Erica, Finkelstein, Dianne M, Goss, Paul E

“…Worldwide, many patients with HER2+ (human epidermal growth factor receptor 2-positive) early breast cancer (BC) do not receive adjuvant trastuzumab. Hazards…”
Get full text

526 - A Phase 1 Study of Parsaclisib in Combination with Investigator Choice of Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma (CITADEL-112): Preliminary Safety Results by Sancho, Juan-Manuel, Lopez-Guillermo, Armando, Abrisqueta, Pau, Kumar, Abhijeet, Cordoba, Raul, Tani, Monica, Zhao, Wanying, Rappold, Erica, Langmuir, Peter, Mims, Martha

Get full text

A Phase 1 Study of Parsaclisib in Combination with Investigator Choice of Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma (CITADEL-112): Preliminary Safety Results by Sancho, Juan-Manuel, Lopez-Guillermo, Armando, Abrisqueta, Pau, Kumar, Abhijeet, Cordoba, Raul, Tani, Monica, Zhao, Wanying, Rappold, Erica, Langmuir, Peter, Mims, Martha

Get full text

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy by Strasser-Weippl, Kathrin, Horick, Nora, Smith, Ian E, O'Shaughnessy, Joyce, Ejlertsen, Bent, Boyle, Frances, Buzdar, Aman U, Fumoleau, Pierre, Gradishar, William, Martin, Miguel, Moy, Beverly, Piccart-Gebhart, Martine, Pritchard, Kathleen I, Lindquist, Deborah, Rappold, Erica, Finkelstein, Dianne M, Goss, Paul E

“…Abstract In resource-constrained environments many patients with human epidermal growth factor receptor 2 (HER2)+ early breast cancer are currently not offered…”
Get full text

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer by Boyle, Frances M, Smith, Ian E, O’Shaughnessy, Joyce, Ejlertsen, Bent, Buzdar, Aman U, Fumoleau, Pierre, Gradishar, William, Martin, Miguel, Moy, Beverly, Piccart-Gebhart, Martine, Pritchard, Kathleen I, Lindquist, Deborah, Amonkar, Mayur, Huang, Yingjie, Rappold, Erica, Williams, Lisa S, Wang-Silvanto, Jing, Kaneko, Tomomi, Finkelstein, Dianne M, Goss, Paul E

“…Summary Background To evaluate health related quality of life (HRQOL) in TEACH, a phase III randomized placebo controlled trial of 12 months of adjuvant…”
Get full text

Prospective Validation of HLA-DRB1 07:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury by Schaid, Daniel J., Spraggs, Colin F., McDonnell, Shannon K., Parham, Laura R., Cox, Charles J., Ejlertsen, Bent, Finkelstein, Dianne M., Rappold, Erica, Curran, Joan, Cardon, Lon R., Goss, Paul E.

“…Purpose Liver injury is a serious adverse event leading to permanent discontinuation of lapatinib in affected patients. This study aimed to validate previously…”
Get full text

Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms by Parham, Laura R, Briley, Linda P, King, Karen S, Byrne, Julie, Rappold, Erica, Goss, Paul E, Spraggs, Colin F

“…Rash is a common side effect of lapatinib treatment. Since human leukocyte antigen ( ) alleles have been implicated in multiple drug-induced cutaneous…”
Get full text

Lack of efficacy of adjuvant lapatinib in HER2-negative breast cancer (HER2–ve BC): Analysis of patients in the TEACH trial by Chavarri Guerra, Yanin, Chan, Arlene, Finkelstein, Dianne M., Chan, Valorie F., Harvey, Vernon J., Lee, Keun Seok, Jain, Minish Mahendra, Petrakova, Katarina, Raina, Vinod, Xu, Binghe, Gomez, Henry, Rappold, Erica, Kaneko, Tomomi, Huang, Yingjie, Goss, Paul E.

“…Abstract only 628 Background: Benefit from trastuzumab (T) in patients (pts) with HER2–ve tumors by central laboratory FISH testing was shown in an exploratory…”
Get full text